Awareness, Case News, Featured, Mesothelioma News, Treatment & Doctors

An Inside Look at a UK Oncologist’s Novel Treatment for Mesothelioma

Treatment for mesothelioma by oncologists

If you were to poll the medical community about the standard care regimen for patients suffering from pleural mesothelioma cancer, you would find the majority are unhappy with the existing strategy.  This general discontent inspired medical oncologist Angus Dalgleish to develop a novel treatment regimen for this cancer-causing disease.  Dr. Dalgleish works at the University of London’s St. George Hospital.  Though Dr. Dalgleish recommended the standard course of treatment for pleural mesothelioma cancer in the past, he is trailblazing a new path that will hopefully help pleural mesothelioma cancer patients across the globe.

Dr. Dalgleish’s Quest to Improve Mesothelioma Treatment

Dr. Dalgleish brought a case report to light in recent months, detailing a unique treatment regimen for pleural mesothelioma cancer patients in the United Kingdom, and possibly beyond if everything goes as planned.  Dr. Dalgleish’s treatment for mesothelioma regimen boosts life expectancy for pleural mesothelioma patients from six months to six years, at least in the case of his first test patient. The novel treatment regimen consists of a sequence of anti-inflammatories including vitamin D3 supplements, a low dosage of naltrexone and a vaccine dubbed IMM-101.  This combination of treatments is meant to boost patient immune system response.

 Dr. Dalgleish was somewhat taken aback as to how well the combination of mesothelioma treatments worked yet the success did not come as a complete shock as it seemed like quite the logical approach prior to implementation.  After all, medical researchers had observed positive responses in patients who had other tumors after they were provided with this unique combination of treatments.  This is precisely why it is sensible that the same approach works for malignant mesothelioma patients.  Dr. Dalgleish’s findings were recently detailed in Respiratory Medicine Case Reports.

About the Test Patient

The test case detailed above involved a male patient in his 60s.  This United Kingdom resident was diagnosed with pleural mesothelioma along with thoracic lymph nodes and lung nodules.  The patient’s first oncologist advised an aggressive treatment approach consisting of a pleurectomy along with decortication surgery.  The oncologist also suggested adjuvant chemotherapy and possibly the use of radiation to boot. 

This avalanche of advice took the patient by surprise, ultimately sending him in Dr. Dalgleish’s direction for an alternative course of treatment for mesothelioma.  After all, there would likely be significant quality of life deteriorations if the patient were to undergo treatment to the extent detailed above.  Dr. Dalgleish concurred, insisting aggressive treatment even had the potential to exacerbate the patient’s condition. 

It appears as though this foresight proved quite prudent considering the positive results of Dr. Dalgleish’s novel treatment regimen.  However, he did not suggest the treatment combination detailed above in a blind manner.  Rather, Dr. Dalgleish was fairly confident in this treatment course as it showed positive results when combined with chemotherapy for patients battling pancreatic cancer.  The use of the forementioned vaccine along with chemotherapy is referred to as an immune modulator as it enhances patient immune response while dampening the system’s negative response.

The Efficacy of Vitamin D3 and Anti-Inflammatories for Pleural Mesothelioma Treatment

Dr. Dalgleish had performed in-depth research on other types of cancers to determine the merits of boosting anti-inflammatory response.  His intuition was the use of vitamin D3 would bolster existing deficiencies of that vitamin in comparably old patients, ultimately enhancing the cancer treatment.  Furthermore, Dr. Dalgleish was aware of several mesothelioma patients who had joined lung cancer clinical trials that analyzed a comparable regimen, producing better results than expected. 

The results of this novel treatment regimen show the test patient had no tumor progression visible in a CT scan one year after the treatment commenced.  As a result, the patient lived significantly longer than the life expectancy that was initially expected.  Fast forward three years and the next CT scan revealed gradual tumor progression that spurred the patient to take zoledronic acid that is commonly used by cancer patients in an attempt to offset high calcium levels.  The patient was also provided with local radiotherapy for a lesion expanding across his chest wall in the location of the original biopsy.

But for cannabis oil, the treatment detailed above is the extent of the test patient’s regimen in the battle against mesothelioma.  No other drugs were taken.  Sadly, this patient passed away in 2019, half a dozen years after the initial diagnosis.  However, this survival period is significantly longer than expected.  It is important to note this brave warrior passed away from disease that moved to the peritoneal cavity as opposed to the initial tumor burden that was first found within his chest. 

A Look to the Future of Mesothelioma Treatment

Dr. Dalgleish insists there will be countless mesothelioma sufferers to come who are excited to pass over the standard care regimen, ultimately giving the medical community an opportunity to further analyze novel treatment regimens through clinical trials. Dr. Dalgleish estimates more than a third of those living in the United Kingdom and suffering from pleural mesothelioma will take an alternative care route as the chances of survival with the traditional course of treatment are quite brief.  Furthermore, the standard care regimen significantly reduces quality of life.

The bottom line is the medical community is still making strides in the treatment of mesothelioma.  There is no single care approach that works significantly better than others at the current moment.  In fact, the standard care approach has the potential to be somewhat toxic.  This is precisely why more medical professionals are likely to follow Dr. Dalgleish’s lead, display irreverence for convention and try new treatment strategies.  If these strategies successfully build on the alternative approach detailed above, they will lengthen mesothelioma patient lifespans while simultaneously improving their quality of life.

If you or a loved one have mesothelioma and require financial assistance, consult with a mesothelioma lawyer.

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *

Send this to a friend